For Health Care Professionals Outside the US

 
 
 

FARYDAK: a first-in-class histone deacetylase (HDAC) inhibitor in multiple myeloma with epigenetic effects1,2

FARYDAK, in combination with bortezomib (BTZ) and dexamethasone (dex), is indicated for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least 2 prior regimens, including BTZ and an immunomodulatory agent1

FARYDAK: a first-in-class HDAC inhibitor in multiple myeloma that may restore epigenetic regulation1-3:

FARYDAK regimen extended progression-free survival (PFS) and deepened response in a phase 3 trial1

In the phase 3 pivotal trial, PANORAMA 1, FARYDAK, in combination with BTZ and dex, led to a clinically relevant and significant increase in progression-free survival (PFS) and more than doubled complete response rates compared with placebo, BTZ, and dex in patients with relapsed and/or refractory multiple myeloma.1

References:

  1. FARYDAK® (panobinostat). EU Summary of Product Characteristics. Novartis AG; August 2015.
  2. San-Miguel JF, Hungria VT, Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014;15(11):1195-1206.
  3. Atadja P. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett. 2009;280(2):233-241.

Is FARYDAK right for your patients? Meet John